Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma

Hamamoto,Junko; Soejima,Kenzo; Yoda,Satoshi; Naoki,Katsuhiko; Nakayama,Sohei; Satomi,Ryosuke; Terai,Hideki; Ikemura,Shinnosuke; Sato,Takashi; Yasuda,Hiroyuki; Hayashi,Yuichiro; Sakamoto,Michiie; Takebayashi,Toru; Betsuyaku,Tomoko

doi:10.3892/mmr.2013.1517

Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma

Authors:
- Junko Hamamoto
- Kenzo Soejima
- Satoshi Yoda
- Katsuhiko Naoki
- Sohei Nakayama
- Ryosuke Satomi
- Hideki Terai
- Shinnosuke Ikemura
- Takashi Sato
- Hiroyuki Yasuda
- Yuichiro Hayashi
- Michiie Sakamoto
- Toru Takebayashi
- Tomoko Betsuyaku
View Affiliations

Affiliations: Department of Pulmonary Medicine, School of Medicine, Keio University, Tokyo 160-8582, Japan, Department of Pathology, School of Medicine, Keio University, Tokyo 160-8582, Japan, Department of Preventive Medicine and Public Health, School of Medicine, Keio University, Tokyo 160-8582, Japan
Published online on: June 11, 2013 https://doi.org/10.3892/mmr.2013.1517
Pages: 456-462

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent advances in the treatment of non-small cell lung cancer (NSCLC) with new agents require accurate histological subtyping at diagnosis to avoid the higher risk of an adverse response and to obtain the maximum therapeutic response. However, interobserver variability, tumor heterogeneity and the degree of differentiation may affect the decision concerning a pathological diagnosis of NSCLC. Therefore, the aim of this study was to identify specific microRNAs (miRNAs) as standardized biomarkers with high sensitivity and specificity in order to distinguish between squamous cell carcinoma (SCC) and adenocarcinoma (AC). Quantitative polymerase chain reaction (qPCR)‑based miRNA array analysis was performed to identify microRNAs differentially expressed between SCC and AC using 86 resected NSCLC samples in addition to adjacent normal tissues. The results were confirmed by independent qRT-PCR assays with the same test samples and 88 additional validation samples, and from this we evaluated the usefulness of the identified miRNAs as biomarkers to distinguish between SCC and AC. Three miRNAs (hsa-miR-196b, hsa-miR-205 and hsa-miR-375) were identified. Discriminant analysis combining the three miRNAs appeared to distinguish SCC from AC accurately in the test and validation samples, demonstrating a sensitivity and specificity of 76 and 80%, and 85 and 83%, respectively. hsa-miR-196b, hsa-miR-205 and hsa-miR-375 were identified as biomarkers capable of distinguishing between lung SCC and lung AC. These newly identified miRNAs may prove to be highly valuable molecular markers for the classification of NSCLC histological subtypes and may contribute to the pathogenesis of each subtype of NSCLC.

View Figures

View References

1	Herbst RS, Heymach JV and Lippman SM: Lung Cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
2	Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
3	Ciuleanu T, Brodowicz T, Zielinski C, et al: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 374:1432–1440. 2009. View Article : Google Scholar : PubMed/NCBI
4	Gridelli C, Ardizzoni A, Douillard JY, et al: Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer. 68:319–331. 2010. View Article : Google Scholar : PubMed/NCBI
5	Rossi G, Pelosi G, Graziano P, Barbareschi M and Papotti M: A reevaluation of the clinical significance of histological subtyping of non-small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments. Int J Surg Pathol. 17:206–218. 2009. View Article : Google Scholar
6	Mok TS, Wu YL and Thongprasert S: Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
7	Kawada I, Soejima K, Watanabe H, et al: An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients. J Thorac Oncol. 3:1096–1103. 2008. View Article : Google Scholar : PubMed/NCBI
8	Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
9	Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 4:259–269. 2006. View Article : Google Scholar
10	Raponi D, Dossey L, Jatkoe T, et al: MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 69:5776–5783. 2009. View Article : Google Scholar : PubMed/NCBI
11	Yanaihara N, Caplen N, Bowman E, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 3:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
12	Colby TV, Noguchi M, Henschke C, et al: Adenocarcinoma. World Health Organization classification of tumours. Pathology and Genetics. Tumours of the Lung, Pleura, Thymus and Heart. Travis WD, Brambilla E, Muller-Hemelink HK and Harris CC: IARC Press; Lyon: pp. 35–44. 2005
13	Hammar SP, Brambilla C, Pugatch B, et al: Squamous cell carcinoma. World Health Organization classification of tumours. Pathology and Genetics. Tumours of the Lung, Pleura, Thymus and Heart. Travis WD, Brambilla E, Muller-Hemelink HK and Harris CC: IARC Press; Lyon: pp. 26–30. 2005
14	Lebanony D, Benjamin H, Gilad S, et al: Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol. 27:2030–2037. 2009. View Article : Google Scholar : PubMed/NCBI
15	Yu L, Todd NW, Xing L, et al: Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer. 127:2870–2878. 2010. View Article : Google Scholar : PubMed/NCBI
16	Bishop JA, Benjamin H, Cholakh H, Chajut A, Clark DP and Westra WH: Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res. 16:610–619. 2010. View Article : Google Scholar : PubMed/NCBI
17	Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM and Gao HJ: Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis. 11:50–54. 2010. View Article : Google Scholar : PubMed/NCBI
18	Popovic R, Riesbeck LE, Velu CS, et al: Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood. 113:3314–3322. 2009. View Article : Google Scholar : PubMed/NCBI
19	Schimanski CC, Berger M, Rahman F, et al: High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. World J Gastroenterol. 15:2089–2096. 2009. View Article : Google Scholar : PubMed/NCBI
20	Wu H and Mo YY: Targeting miR-205 in breast cancer. Expert Opin Ther Targets. 13:1439–1448. 2009. View Article : Google Scholar : PubMed/NCBI
21	Childs G, Fazzari M, Kung G, et al: Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol. 17:736–745. 2009. View Article : Google Scholar : PubMed/NCBI
22	Greene SB, Gunaratne PH, Hammond SM and Rosen JM: A putative role for microRNA-205 in mammary epithelial cell progenitors. J Cell Sci. 123:606–618. 2010. View Article : Google Scholar : PubMed/NCBI
23	Mathé EA, Nguyen GH, Bowman ED, et al: MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res. 15:6192–6200. 2009.PubMed/NCBI
24	El Ouaamari A, Baroukh N, Martens GA, Lebrun P, Pipeleers D and van Obberghen E: miR-375 targets 3’-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic beta-cells. Diabetes. 57:2708–2717. 2008.
25	Saji H, Tsuboi M, Matsubayashi J, et al: Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy. Anticancer Drugs. 21:89–83. 2010. View Article : Google Scholar : PubMed/NCBI
26	Kozuki T, Fujimoto N, Ueoka H, et al: Complexity in the treatment of pulmonary large cell neuroendocrinecarcinoma. J Cancer Res Clin Oncol. 131:147–51. 2005. View Article : Google Scholar : PubMed/NCBI